

Supplementary Material

Evaluation of Patient Reported Symptoms and Functioning after Treatment for Endometrial Cancer

Monika Sobočan^{1,2,*}, Dorotea Gašpar², Estera Gjuras² and Jure Knez^{1,2}

¹ Division of Gynecology and Perinatology, University Medical Centre Maribor, 2000 Maribor, Slovenia

² Department of Obstetrics and Gynecology, Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia

* Correspondence: monika.sobocan@gmail.com

Table S1. Correlational matrix of symptoms.

| | <u>Lymph-edema</u> | <u>Urological</u> | <u>GI</u> | <u>PoorBody</u> | <u>BackPain</u> | <u>Tingling and numbness</u> | <u>Muscular pain</u> | <u>Hair loss</u> | <u>Taste change</u> |
|------------------------------|--------------------|-------------------|---|---|---|---|---|---|---|
| <u>Lymph-edema</u> | N/A | | rs = 0.374, p < 0.001** (CI95 0.164-.561) | rs = 0.226, p = 0.055 (CI95 0.080-.164) | rs = 0.095, p = 0.423 (CI95 0.080-.097) | rs = 0.293, p = 0.012* (CI95 0.062-.071) | rs = 0.490, p < 0.001** (CI95 0.264-.271) | rs = 0.516, p < 0.001** (CI95 0.350-.359) | rs = 0.076, p = 0.523 (CI95 -.183-.276) |
| <u>Urological</u> | | N/A | rs = 0.374, p < 0.001** (CI95 0.164-.561) | rs = 0.436, p < 0.001** (CI95 0.271-.633) | rs = 0.145, p = 0.220 (CI95 0.019-.453) | rs = 0.251, p = 0.032* (CI95 0.002-.439) | rs = 0.376, p < 0.001** (CI95 0.197-.584) | rs = 0.270, p = 0.021* (CI95 0.034-.464) | rs = 0.322, p = 0.005** (CI95 0.067-.490) |
| <u>GI</u> | | | rs = 0.226, p = 0.055 (CI95 0.080-.500) | rs = 0.436, p < 0.001** (CI95 0.271-.633) | rs = 0.133, p = 0.264 (CI95 0.036-.466) | rs = 0.409, p < 0.001** (CI95 0.196-.583) | rs = 0.476, p < 0.001** (CI95 0.345-.679) | rs = 0.213, p = 0.070 (CI95 0.030-.461) | rs = 0.126, p = 0.287 (CI95 -.133-.323) |
| <u>PoorBody</u> | | | rs = 0.095, p = 0.423 (CI95 -.097-.355) | rs = 0.145, p = 0.220 (CI95 0.019-.453) | rs = 0.133, p = 0.264 (CI95 0.036-.466) | rs = 0.409, p < 0.001** (CI95 0.196-.392) | rs = 0.476, p < 0.001** (CI95 0.345-.466) | rs = 0.213, p = 0.070 (CI95 0.030-.461) | rs = 0.126, p = 0.287 (CI95 -.133-.323) |
| <u>BackPain</u> | | | rs = 0.293, p = 0.012* (CI95 0.062-.486) | rs = 0.251, p = 0.032* (CI95 0.002-.439) | rs = 0.409, p < 0.001** (CI95 0.196-.583) | rs = 0.128, p = 0.279 (CI95 -.055-.392) | rs = 0.098, p = 0.409 (CI95 0.036-.626) | rs = 0.141, p = 0.233 (CI95 -.120-.616) | rs = 0.059, p = 0.619 (CI95 -.079-.371) |
| <u>Tingling and numbness</u> | | | rs = 0.293, p = 0.001** (CI95 0.264-.628) | rs = 0.251, p = 0.001** (CI95 0.197-.584) | rs = 0.409, p < 0.001** (CI95 0.345-.679) | rs = 0.128, p = 0.279 (CI95 0.036-.626) | rs = 0.460, p < 0.001** (CI95 0.261-.626) | rs = 0.446, p < 0.001** (CI95 0.244-.584) | rs = 0.059, p = 0.619 (CI95 0.034-.464) |
| <u>Muscular pain</u> | | | rs = 0.516, p < 0.001** (CI95 0.350-.683) | rs = 0.270, p = 0.021* (CI95 0.034-.464) | rs = 0.213, p = 0.070 (CI95 0.030-.461) | rs = 0.141, p = 0.233 (CI95 -.120-.334) | rs = 0.446, p < 0.001** (CI95 0.244-.616) | rs = 0.387, p < 0.001** (CI95 0.198-.584) | rs = 0.160, p = 0.413 (CI95 -.161-.337) |
| <u>Hair loss</u> | | | rs = 0.076, p = 0.523 (CI95 -.183-.276) | rs = 0.322, p = 0.005** (CI95 0.067-.490) | rs = 0.126, p = 0.287 (CI95 -.133-.323) | rs = 0.059, p = 0.619 (CI95 0.079-.371) | rs = 0.160, p = 0.618 (CI95 -.161-.297) | rs = 0.097, p = 0.413 (CI95 0.034-.464) | rs = 0.907, p < 0.001** (CI95 0.936-.974) |
| <u>Taste change</u> | | | rs = 0.101, p < 0.034 (CI95 -.166-.292) | rs = 0.351, p = 0.002** (CI95 0.088-.506) | rs = 0.176, p = 0.136 (CI95 0.074-.375) | rs = 0.090, p = 0.448 (CI95 0.074-.375) | rs = 0.141, p = 0.233 (CI95 0.074-.343) | rs = 0.161, p = 0.025* (CI95 0.113-.524) | rs = 0.907, p < 0.001** (CI95 0.936-.974) |

Table S2. Impact of surgical therapy on Patient Reported Outcomes

| | Minimally invasive therapy (Mean, SD) | Open surgery (Mean, SD) | Significance |
|-------------------------|--|------------------------------------|---------------------|
| Lymphoedema | 30.0 (26.2) | 38.7 (28.7) | <i>p</i> > 0.221 |
| Urological | 31.6 (26.8) | 32.6 (26.8) | <i>p</i> . > 855 |
| Gastrointestinal | 21.6 (16.7) | 23.4 (18.7) | <i>p</i> . > 881 |
| Poor Body image | 12.0 (22.2) | 11.7 (22.9) | <i>p</i> . > 0.999 |
| Back Pain | 47.8 (30.0) | 56.8 (35.4) | <i>p</i> > 0.249 |
| Tingling and numbness | 37.4 (32.0) | 33.6 (31.9) | <i>p</i> > 0.688 |
| Muscular pain | 34.4 (30.0) | 46.7 (32.9) | <i>p</i> > 0.126 |
| Hair loss | 20.2 (28.0) | 13.1 (29.8) | <i>p</i> > 0.133 |
| Taste change | 20.2 (28.0) | 10.2 (29.2) | <i>p</i> > 0.031 |
| Sexual interest | 14.3 (18.4) | 16.2 (22.4) | <i>p</i> > 0.892 |
| Sexual activity | 12.8 (19.4) | 11.8 (19.3) | <i>p</i> > 0.818 |
| Sexual enjoyment | 44.2 (27.4); (<i>n</i> = 19) | 46.3 (30.5); (<i>n</i> = 8) | <i>p</i> > 0.955 |
| Sexual/Vaginal problems | 23.9 (25.4); (<i>n</i> = 19) | 26.9 (22.3); (<i>n</i> = 8) | <i>p</i> > 0.607 |

Table S3. Impact of lymph node treatment on Patient Reported Outcomes

| | SNB (Mean, SD) | LND (Mean, SD) | SNB with LND (Mean, SD) | no LN treatment (Mean, SD) | Significance |
|-------------------------|-------------------------------|------------------------------|------------------------------------|---------------------------------------|---------------------|
| Lymphoedema | 28.1 (25.9) | 39.7 (28.9) | 26.6 (21.3) | 35.1 (29.9) | <i>p</i> > 0.488 |
| Urological | 28.4 (23.8) | 36.0 (27.3) | 26.4 (29.2) | 35.8 (31.4) | <i>p</i> > 0.734 |
| Gastrointestinal | 21.1 (14.3) | 20.9 (18.7) | 24.9 (13.1) | 25.8 (23.5) | <i>p</i> > 0.830 |
| Poor Body image | 11.3 (22.4) | 9.2 (17.8) | 9.6 (18.9) | 19.6 (31.0) | <i>p</i> > 0.738 |
| Back Pain | 48.5 (28.2) | 60.9 (31.8) | 33.9 (19.3) | 47.4 (41.3) | <i>p</i> > 0.191 |
| Tingling and numbness | 30.0 (28.4) | 36.7 (30.8) | 52.9 (26.0) | 39.1 (42.2) | <i>p</i> > 0.374 |
| Muscular pain | 37.4 (29.8) | 42.7 (36.0) | 33.9 (19.3) | 36.4 (33.3) | <i>p</i> > 0.924 |
| Hair loss | 15.0 (21.6) | 12.2 (26.4) | 19.1 (37.8) | 33.6 (37.6) | <i>p</i> > 0.204 |
| Taste change | 13.8 (21.4) | 10.7 (26.1) | 19.1 (37.8) | 33.6 (37.6) | <i>p</i> > 0.126 |
| Sexual interest | 13.9 (17.0) | 16.9 (22.7) | 9.7 (16.6) | 16.9 (22.7) | <i>p</i> > 0.902 |
| Sexual activity | 15.1 (19.5) | 10.8 (19.2) | 0 (.00) | 16.9 (22.7) | <i>p</i> > 0.192 |
| Sexual enjoyment | 44.8 (29.7); (<i>n</i> = 12) | 52.7 (32.5); (<i>n</i> = 7) | 0; (<i>n</i> = 1) | 43.4 (16.1); (<i>n</i> = 7) | <i>p</i> > 0.417 |
| Sexual/Vaginal problems | 19.2 (16.7); (<i>n</i> = 12) | 30.6 (25.6); (<i>n</i> = 7) | 0; (<i>n</i> = 1) | 32.1 (33.0); (<i>n</i> = 7) | <i>p</i> > 0.451 |

LN: lymph-node, SNB: sentinel lymph-node biopsy, LND: lymphadenectomy, SNB with LND: SNB with contralateral LND.